about
Whole-genome analysis of sporadic amyotrophic lateral sclerosisMutant genes responsible for Parkinson's diseaseExcess circulating alternatively activated myeloid (M2) cells accelerate ALS progression while inhibiting experimental autoimmune encephalomyelitisTREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis.Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS.Mutations in NR4A2 associated with familial Parkinson disease.Mechanisms of disease pathogenesis in amyotrophic lateral sclerosis. A central role for calcium.TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis.Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice.Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis.Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosisProtective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis.Oxidative Stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis.Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.AALSS.Promoting excellence in end-of-life care in ALS.2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases.Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis.An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditionsRegulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survivalCD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS.An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man studyDeciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis.Novel therapeutic targets in neurodegenerative diseases: lessons from amyotrophic lateral sclerosis.Extracellular mutant SOD1 induces microglial-mediated motoneuron injury.Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms.Microglia in ALS: the good, the bad, and the resting.T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?Toward more efficient clinical trials for amyotrophic lateral sclerosis.ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity.Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis.TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss.Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes.A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy.Major stressors facing patients with amyotrophic lateral sclerosis (ALS): a survey to identify their concerns and to compare with those of their caregivers.Epigallocatechin gallate prevents oxidative-stress-induced death of mutant Cu/Zn-superoxide dismutase (G93A) motoneuron cells by alteration of cell survival and death signals.A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options.Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutationsPeripheral nerve inflammation in ALS mice: cause or consequence.CD4+ T cells mediate cytotoxicity in neurodegenerative diseases.
P50
Q24329076-F479B80D-2478-46F1-9F17-BE77785FF070Q28250168-47CF6F12-0189-42C8-B9C1-E53069FA3838Q28743158-74941858-6BDE-4FA7-9C67-6AF676F7218DQ33864853-324CE90E-EC59-476D-AD74-596A28528435Q34019767-EF472E66-DC0E-42ED-8277-3941B76B0FE6Q34166532-3FBD8363-30C3-49CF-98D3-E88EAFFC0EA3Q34573518-74DD7882-A3D6-4747-913A-7B8F3F505AEAQ34979308-5FE7BF9C-ACF3-4F90-86FC-0F62C0F8E798Q34988159-0DDD4039-7565-4E2E-8920-C971E5DB5A40Q34992177-086FCA88-2E48-43C6-BC6B-328311AB8BECQ35094527-CB698BD2-3035-4CA6-B143-EA05558EC4EBQ35501874-FB370EA3-C50A-4D6C-97BA-1EBF5469ADDAQ35564247-66D67B96-EDE8-4372-9BD3-C7F82C5AE5EFQ35624305-6415653A-1C2E-4156-B59B-8990C3B26802Q35932135-4498D37A-E636-4663-9E77-46C182D15923Q36267647-2CCFF31E-A94D-4A1E-B40A-ADA318088247Q36381232-985DD2F5-F6A6-4A6C-BEB7-88B0E9BCA6FAQ36503292-B5E89A2D-4BBD-4539-ADAA-38C402A4B675Q36551001-DFA2AB2E-53C8-4D8B-BFD9-1799FED94995Q36602163-749617A6-2810-4162-846A-08F0CF103628Q36899833-B5117F6A-E6BE-43F6-A795-933F9E380F0CQ37015657-5F7B209F-07E4-4917-BB34-F48E9A824017Q37189268-D65E7B43-E7DB-4B8B-B488-2D317BCC9CE3Q37247387-04E9ED31-5836-4F62-A7DE-B350CC0B3E1DQ37442209-5A9C4754-E4BC-4558-BF70-CC04AFFDF36FQ37498880-F884EDE6-A756-4F18-88A2-7590AFC5DD4EQ37592030-B2D58CCD-1F98-476B-93F9-84A83B51879BQ37625319-E289B17A-C751-47A4-AAAF-C5A6F6E2B687Q37644480-EFC6A035-ACCE-4931-A956-A79A8E37B1FCQ37677431-8DA5BEE6-DA18-4A84-8E44-A706F7C54053Q38123758-9650CEFF-FDB0-47F8-A74C-D288E615B7A8Q38697913-02928E7C-E48C-4FA6-A627-52F55B568AB2Q38822774-0C3F6C86-80B8-4057-BA30-C4A300E21FC0Q39516905-D948D285-2A53-4BAB-B350-AD335D35C454Q40502541-7051EE80-AED2-4919-B379-C653840EFE9AQ40520911-5F9089B1-1831-42DD-97C3-6D99F2C67A64Q40595257-33610D88-5C84-4B09-B224-2C1B30BCA0BDQ41066718-91651205-8508-43DF-9048-8071321ABBF3Q42580455-EA92D364-AD30-4ADE-9925-7FF252B39A36Q43213561-9BD7ECFD-19B0-4DF7-BEDC-70EA698196E0
P50
name
Stanley H Appel
@en
Stanley H Appel
@nl
type
label
Stanley H Appel
@en
Stanley H Appel
@nl
prefLabel
Stanley H Appel
@en
Stanley H Appel
@nl